A peptide from the thymus
Thymosin alpha-1 is a 28-residue peptide originally isolated from thymus tissue, the organ where T cells mature. It was among the first thymic peptides to be characterised and synthesised, which is why its literature is older and larger than most of this catalogue.
It has been used clinically under a trade name in a number of countries, principally in the context of chronic hepatitis B and as an adjuvant. That is a matter of regulatory record rather than something we are claiming.
If your search was what is thymosin alpha-1, the short answer is a 28-residue thymic peptide with a genuine clinical record abroad and a research-only status here. Almost everything worth understanding about it follows from holding those two facts apart rather than letting them blur.
Approval elsewhere is not approval here
This is where the distinction that runs through this whole site becomes concrete. A compound approved in one jurisdiction under a trade name, manufactured to pharmaceutical standards and dispensed through a pharmacy, is a different product from research material carrying a certificate of analysis.
Same molecule name, different dossier, different obligations, different intended use. Anyone blurring that line is doing you a disservice, and it is the single most important thing to understand about this particular compound.
The gap between an approved medicine and research material is not a marketing nuance but a legal one, and it decides what may lawfully be said and done with each. Where that line runs is set out on the page on whether research peptides are legal, and it applies with particular force to a compound that is a licensed drug somewhere else.
| Length | 28 amino acids |
| Origin | Isolated from thymus tissue |
| Research focus | T cell maturation, immune modulation |
| Regulatory status | Approved in some countries under a trade name |
| Format | Pre-filled peptide pen |
| Purity | ≥ 99% (HPLC) |
| Evidence base | Includes controlled human studies |
| Category | Research use only |
Physical and analytical properties. No line is a statement about outcomes.
What the research examines
The work concentrates on T cell maturation and function, and on how immune responses are modulated rather than simply increased. That distinction matters: the research question is about regulation, not about making the immune system do more of something.
Because a clinical literature exists, this is one of the few compounds where you can read properly controlled human studies rather than extrapolating from animal work.
What that literature contains is worth being specific about. The studies are indexed under the sequence name on PubMed, and the trials behind them are listed on ClinicalTrials.gov. Being able to name the design of a study, rather than the conclusion someone drew from it, is the practical difference between this file and most of the others in this catalogue.
Why the certificate matters even for a documented peptide
A long clinical history does not turn the pen in front of you into the licensed product; it makes the identity question more important, not less, because the name is shared and the dossier is not. What a certificate of analysis confirms is that this batch is the sequence it claims to be.
That is the narrow, honest guarantee research material can offer: identity and purity, documented per batch and released against a set standard. The quality standard behind that release is the same one applied across the catalogue, whatever a compound’s regulatory status happens to be elsewhere.
Thymosin Alpha-1 in the catalogue
Nothing ships below 99% purity, and every shipment maps to a certificate you can read.
Where Thymosin Alpha-1 fits in
Three articles that answer the questions this one raises.
About Thymosin Alpha-1
The recurring questions, answered plainly.